The page below is a sample from the LabCE course HER2 Testing in Breast Cancer. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about HER2 Testing in Breast Cancer (online CE course) »
How to Subscribe
Histology CE Package$65 Add to cart
Individual course$20 Add to cart

HER2 Protein Overexpression and Gene Amplification

The HER2 protein is overexpressed in 20-30% of breast cancers. Overexpression is often the result of gene amplification and is associated with poor prognosis in breast cancer patients. Patients with overexpression are eligible for therapy with the monoclonal antibody trastuzumab, known as Herceptin®, which may be used as a treatment in HER2 amplified breast cancer.